Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K
Stem Cell Culture01:17

Stem Cell Culture

5.2K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
5.2K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Embryonic Stem Cells00:58

Embryonic Stem Cells

28.7K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
28.7K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Source And Potency Of Stem Cells01:27

Source And Potency Of Stem Cells

4.9K
Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injectable alginate hydrogels improve the effects of subretinal hiPSC-derived RPE cell therapy on retinal degeneration in rats.

Materials today. Bio·2026
Same author

Cholesterol analogs modulate lipid nanoparticle performance for mRNA delivery after lyophilization and enable ocular disease therapy.

Materials today. Bio·2026
Same author

Correction: Designed peptide-grafted hydrogels for human pluripotent stem cell culture and differentiation.

Journal of materials chemistry. B·2026
Same author

Enrichment of colon cancer stem cells via polymeric porous filters with different zeta potentials.

Regenerative biomaterials·2026
Same author

Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues.

Regenerative biomaterials·2025
Same author

Conjugation of peptides to a dendrimer surface to promote the proliferation and differentiation of human pluripotent stem cells into cardiomyocytes and retinal pigment epithelium.

Biomaterials·2025

Related Experiment Video

Updated: Jul 17, 2025

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System
08:00

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Published on: May 14, 2015

31.8K

Universal and hypoimmunogenic pluripotent stem cells for clinical usage.

Tzu-Cheng Sung1, Kailibinuer Maitiruze1, Jiandong Pan1

  • 1State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.

Progress in Molecular Biology and Translational Science
|September 7, 2023
PubMed
Summary

Creating universal hypoimmunogenic human pluripotent stem cells (hPS) is crucial for accessible cell therapies. Engineering these cells reduces the need for extensive resources and technicians in stem cell banking.

Keywords:
Cell therapyHuman leukocyte antigenHypoimmunogenic hPS cellsImmune privilegeOff-the-shelf cellsUniversal hPS cells

More Related Videos

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions
10:48

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions

Published on: November 26, 2014

7.9K
Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions
09:34

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions

Published on: November 27, 2017

9.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System
08:00

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Published on: May 14, 2015

31.8K
Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions
10:48

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions

Published on: November 26, 2014

7.9K
Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions
09:34

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions

Published on: November 27, 2017

9.3K

Area of Science:

  • Stem Cell Biology
  • Immunology
  • Genetic Engineering

Background:

  • Clinical trial-grade human pluripotent stem (hPS) cells are needed for off-the-shelf cell therapies.
  • Current stem cell banking requires substantial financial support and technical staff for cell maintenance.
  • Developing universal or hypoimmunogenic hPS cells can streamline cell therapy logistics.

Purpose of the Study:

  • To explore methods for creating hypoimmunogenic or universal hPS cells.
  • To discuss the advantages and disadvantages of genome editing techniques for this purpose.

Main Methods:

  • Genome editing using CRISPR/Cas9 to knock out immune-related genes (e.g., β2-Microglobulin, HLA class Ia).
  • Knocking in immune-evasive genes (e.g., CD47, HLA-G, PD-L1).
  • Investigating alternative approaches without genome editing.

Main Results:

  • β2-Microglobulin knockout hPS cells lacked HLA class I but activated natural killer cells.
  • Strategies involving homozygous single HLA class I allele expression were proposed to evade immune cells.
  • Engineered hPS cells with knocked-out major HLA class Ia and knocked-in CD47, HLA-G, and PD-L1 showed promise.
  • Genome-editing-free universal hPS cells demonstrated evasion of T cells, macrophages, and natural killer cells.

Conclusions:

  • Universal hypoimmunogenic hPS cells hold significant potential for advancing cell therapy applications.
  • Genome editing and novel approaches are key to developing off-the-shelf stem cell solutions.
  • Reducing immunogenicity is critical for the widespread clinical use of hPS cell-based therapies.